Case report: Approaches to treatment-refractory and super-refractory glutamic acid decarboxylase antibody-spectrum disorders.
Front Immunol
; 14: 1297340, 2023.
Article
en En
| MEDLINE
| ID: mdl-38259445
ABSTRACT
Background:
Glutamic acid decarboxylase antibody-spectrum disorders (GAD-SDs) include a group of autoimmune neurological diseases associated with neuronal excitability, most noticeably stiff person syndrome. Immune modulators are the mainstay of treatment, but a significant number of patients remain refractory.Methods:
We present our single-center experience of eight cases of GAD-SD, two of which were refractory to immune modulatory treatments.Results:
Of the two cases that were refractory to immunomodulation, one showed significant improvement with bilateral globus pallidus interna deep brain stimulation (GPi DBS) placement, and the other showed significant improvement with autologous hematopoietic stem cell transplant (aHSCT).Discussion:
To our knowledge, this is the first instance of GPi DBS placement being noted to improve GAD-SD movements.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Enfermedades Autoinmunes del Sistema Nervioso
/
Glutamato Descarboxilasa
Idioma:
En
Revista:
Front Immunol
Año:
2023
Tipo del documento:
Article